Sa'ar Yaniv

Stock Analyst at Roth Capital

(1.00)
# 2,840
Out of 4,667 analysts
3
Total ratings
33.33%
Success rate
4.06%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Sa'ar Yaniv

Galectin Therapeutics
Oct 19, 2017
Initiates: Buy
Price Target: $8
Current: $2.82
Upside: +184.19%